-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Addition of Nivolumab to Neoadjuvant Chemotherapy in NSCLC: Results of CheckMate-816
Platinum-based chemotherapy, given either before (neoadjuvant) or after (adjuvant) surgery for stage II and III NSCLC is associated with a 5% improvement in long-term survival. Despite consensus guidelines recommending its use, uptake of chemotherapy for earlier-stage NSCLC remains low when compared with other common cancers, and, currently, most chemotherapy that is given is delivered postoperatively.…
-
Veterans Health Administration’s Lung Precision Oncology Program Helps Individualize Treatment
Lung cancer is not only the leading cause of cancer deaths in the United States, with nearly 229,000 people diagnosed annually, but is also the deadliest cancer affecting patients of the Veterans Health Administration (VHA). More than 900,000 Veterans are at risk of developing lung cancer because of advanced age, environmental exposures, and/or smoking, according…
-
Cardiac Toxicity of Lung Cancer Radiotherapy
A 65-year-old patient with stage III NSCLC comes to your clinic to discuss concurrent chemoradiotherapy. She has a history of ischemic heart disease, and 4 years ago an angiogram demonstrated minor coronary artery disease that did not require intervention. Her angina is well-controlled on medication, and she only rarely uses her glyceryl trinitrate spray. She…
-
Hippocampal-Sparing Brain Irradiation: The Future of Brain Metastases Treatment and Prevention?
Brain metastases (BMs) are frequently diagnosed in patients with SCLC and NSCLC, although the incidence is highest in SCLC.1 ,2 ,3 BMs are a negative prognostic factor and are associated with a decreased quality of life (QoL).2 ,4 Therefore, it is important to prevent or to treat them early. Prophylactic cranial irradiation (PCI) significantly reduces…
-
Second-Line, Biomarker-Driven Therapies for Squamous NSCLC: Report on Lung-MAP SWOG S1400
The Lung Master Protocol (Lung-MAP; S1400) was a biomarker-driven master protocol. This trial was originally designed to address the relative paucity of effective, targeted therapies in squamous cell lung cancer, compared to non-squamous NSCLC subtypes.1 This trial was initiated in 2014, when the standard-of-care treatment for patients with advanced squamous cell lung cancer consisted of…
-
The IASLC Language Guide: A Lexicon of Healing for Lung Cancer and Beyond
America’s decades-long war on smoking has been remarkably successful in reducing smoking rates, but the unintended consequences include stigmatizing people who smoke and people with lung cancer. Sadly, those dealing with lung cancer continually encounter hurtful statements born of ignorance or thoughtlessness (questions such as, “Do you smoke?”), along with the burden of having to…
-
China’s Domestic PD-1/PD-L1 Inhibitors Demanding Global Attention
The growth of these domestic drugs should shine a light on the lack of diversity in many international clinical trials in immunotherapy.
-
Surgical Outcomes of CheckMate816 Support Use of Neoadjuvant Nivolumab Plus Chemotherapy for NSCLC
Patients treated with neoadjuvant combination nivolumab plus chemotherapy who had resectable NSCLC underwent surgical resection at similar rates and timeframes to those undergoing neoadjuvant chemotherapy, according to a presentation of surgical outcomes data from the CheckMate 816 trial (Abstract 8503). Data previously presented at the AACR 2021 Annual Meeting showed that nivolumab plus chemotherapy resulted…
-
VIOLET Data Establishes VATS as Standard for Early-Stage Resectable NSCLC
A presentation of updated results from the VIOLET study comparing video-assisted thoracoscopic surgery (VATS) with open lobectomy showed that improvements in pain, in-hospital complications, and shorter hospital stay previously reported after VATS were achieved without any compromise to oncologic outcomes at 1 year. In addition, patients who underwent VATS had significantly improved physical function at…
-
3D Model of Lung Nodules Reduces Anxiety for Patients While Helping Them Understand Their Cancer Risk
Thousands of Americans each year learn that CT chest screening has identified nodules on their lungs and, as a result, they often experience distress, fear, and confusion about their cancer risk, which may be compounded by miscommunications with their providers. Theresa Roelke, MSN, APRN-AGPCNP, a nurse practitioner who specializes in geriatrics and manages the lung…